ERYTech Pharma ADR

Loading quotes...

Forecast

Buy	1
Hold	0
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, ERYTech Pharma ADR had revenue of €0 and net profit of -€228k

(EUR)	2022	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-228k	99.58%
EBITDA	4.57m	109.86%

Fundamentals

Metric	Value
Market capitalization	€42.97m
Number of shares	60.75m
52-week high/low	€1.33 - €0.27
Dividends	No
Beta	2.13
P/E ratio	-0.02
PEG ratio	0.00
P/B ratio	0.02
P/S ratio	0.76

Company profile

ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.